Skip to main content
SpringerLink
Log in

Hepatocellular carcinoma

Sorafenib—for once age is not an issue

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide clinicians making these decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).

  2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  Google Scholar 

  3. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).

    Article  CAS  Google Scholar 

  4. Jo, M. et al. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol. Res. http://dx.doi.org/10.1111/hepr.12308.

  5. Iavarone, M. et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54, 2055–2063 (2011).

    Article  CAS  Google Scholar 

  6. Cho, J. Y. et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int. 33, 950–957 (2013).

    Article  CAS  Google Scholar 

  7. Al Hasani, F. et al. Factors affecting screening for hepatocellular carcinoma. Ann. Hepatol. 13, 204–210 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatology, University Clinic of Visceral Surgery and Medicine, Inselspital, Bern, CH-3010, Switzerland

    Jean-François Dufour

Authors
  1. Jean-François Dufour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-François Dufour.

Ethics declarations

Competing interests

J.-F.D has been an advisor for Bayer, BMS, Gilead Science, Janssen Cilag, Jennerex, Merck, Novartis and Roche, and has spoken and taught for Bayer, Boehringer-Ingelheim, Novartis and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dufour, JF. Sorafenib—for once age is not an issue. Nat Rev Gastroenterol Hepatol 11, 273–274 (2014). https://doi.org/10.1038/nrgastro.2014.48

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.48

  • Springer Nature Limited

This article is cited by

Search

Navigation